Dianthus Therapeutics, Inc. $DNTH Shares Bought by Palumbo Wealth Management LLC

Palumbo Wealth Management LLC grew its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 125.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,967 shares of the company’s stock after acquiring an additional 8,317 shares during the period. Palumbo Wealth Management LLC’s holdings in Dianthus Therapeutics were worth $617,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Parkside Financial Bank & Trust lifted its position in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 540 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $64,000. Tower Research Capital LLC TRC lifted its position in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares during the period. Finally, Glenmede Investment Management LP acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $213,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research reports. Robert W. Baird lifted their price target on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Wedbush lifted their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Truist Financial lifted their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $117.30.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $86.20 on Wednesday. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $88.49. The company has a market capitalization of $3.83 billion, a P/E ratio of -21.02 and a beta of 1.22. The business has a 50 day moving average price of $65.23 and a 200 day moving average price of $48.78.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 314,797 shares of company stock valued at $25,825,163. 16.56% of the stock is currently owned by company insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.